select trial semaglutide results semaglutide showed a 20% reduction in major adverse cardiovascular events - Ly3437943 semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by 20 SELECT Trial Semaglutide Results: A Comprehensive Look at Cardiovascular Benefits and Weight Management

Retatrutide The SELECT trial, a landmark study investigating the cardiovascular outcomes of semaglutide in individuals with overweight or obesity but without diabetes, has yielded significant results. This extensive research, involving 17,604 participants, compared the effects of once-weekly subcutaneous semaglutide 2.Semaglutide and Cardiovascular Outcomes in Obesity ...4 mg against a placebo, serving as an adjunct to standard care. The overarching goal was to determine if semaglutide could reduce the risk of major adverse cardiovascular events (MACE) in this population.

A key finding from the SELECT trial is the demonstration of semaglutide's ability to induce clinically significant weight lossSELECT Trial: Semaglutide Cuts Major CVD Risk by 20% .... It’s understood that semaglutide itself is a glucagon-like peptide-1 (GLP-1) receptor agonist, and its impact extends beyond mere weight reduction. The results consistently show decreases in body weight and waist circumference among participants receiving semaglutideSELECT Trial. Specifically, at 208 weeks, the trial reported that semaglutide produced clinically significant weight loss and improvements in anthropometric measurements compared to placebo. This reduction in body weight has been linked to a more favorable cardiovascular profile.

However, the SELECT trial results have also highlighted that semaglutide's cardiovascular benefits are not solely attributed to weight loss. While weight reduction plays a role, new analyses suggest that semaglutide protects the heart beyond weight loss. Data indicates a linear reduction in MACE as both baseline body weight and waist circumference decrease, yet the cardiovascular protection offered by semaglutide appears to be more profound than what can be explained by weight reduction alone. This suggests an independent cardioprotective mechanism at play.

The core results of the SELECT trial are striking: semaglutide showed a 20% reduction in major adverse cardiovascular events in adults with overweight or obesity. These MACE were comprised of cardiovascular death, nonfatal myocardial infarction, and stroke.2025年5月13日—Data showed thatwithin six months of treatment, a reduction in risk of CV deathwas observed for patients taking Wegovy®related to CV death ( ... This significant reduction in cardiovascular events and weight underscores the drug's multifaceted benefits.2024年9月12日—Once-weekly subcutaneoussemaglutidewas associated with a decreased risk of MACE comprised of CV death, nonfatal MI, and stroke compared with placebo. Furthermore, subgroup analyses have revealed that semaglutide reduced CV risk by 20% across various patient profiles, including those with a higher baseline risk.

Deeper dives into the SELECT trial data have provided further insights. A prespecified analysis revealed that semaglutide treatment reduced MACE and a heart failure composite endpoint. In fact, semaglutide improved all outcome measures in patients with heart failure at random assignment compared with those without heart failure, exhibiting a hazard ratio of 0.Semaglutide's CV Effects Only Partially Tied to Weight Loss72What were the results of the SELECT trial of semaglutide .... Additionally, semaglutide consistently reduced all cardiovascular outcomes in these patients, reinforcing its broad cardioprotective potential.2024年9月12日—Once-weekly subcutaneoussemaglutidewas associated with a decreased risk of MACE comprised of CV death, nonfatal MI, and stroke compared with placebo.

The timing of these benefits is also noteworthyIn new SELECT trial analysis, early reduction .... Data emerged showing that within six months of treatment, a reduction in risk of CV death was observed for patients taking Wegovy® (a brand of semaglutide). This early efficacy suggests that individuals could experience protective effects relatively quickly.

The SELECT trial has unequivocally demonstrated that treatment with weekly injectable semaglutide 2.4 mg was superior to placebo in mitigating cardiovascular riskSemaglutide's CV Effects Only Partially Tied to Weight Loss. This drug has emerged as a significant advancement, offering a dual benefit of weight management and cardiovascular risk reduction for a substantial population. Further research, such as the SELECT-LIFE study, is even exploring the long-term effects of semaglutide in individuals who participated in the original SELECT Cardiovascular Outcomes Trial, aiming to provide even more comprehensive data on its lasting impactSemaglutide Superior to Tirzepatide in Reducing Cardiovascular Event Risk. In summary, the SELECT trial results offer compelling evidence for the role of semaglutide in improving cardiovascular health and managing weight in eligible individuals.